Şunu aradınız:: hepaticamente (Portekizce - İngilizce)

aproximadamente 10% do metotrexato administrado é metabolizado intra-hepaticamente.
approximately 10% of the administered methotrexate is metabolised intrahepatically.

o compromisso renal grave pode influenciar a eliminação de medicamentos eliminados hepaticamente.
severe renal impairment may influence the elimination of hepatically eliminated medicinal products.

as semividas mais longas observadas nos doentes hepaticamente comprometidos atrasam o estabelecimento do estado estacionário.
the longer half-lives observed in hepatically impaired patients delay reaching steady state.

as semi- vidas mais longas observadas nos doentes hepaticamente comprometidos atrasam o estabelecimento do estado estacionário.
the longer half-lives observed in hepatically impaired patients delay reaching steady state.

num ensaio de 20 semanas, a pioglitazona, para além de reduzir os triglicéridos em jejum, reduziu a hipertrigliceridemia pós-prandial através dum efeito quer sobre os triglicéridos absorvidos quer sobre os triglicéridos sintetizados hepaticamente.
in a 20-week study, as well as reducing fasting triglycerides, pioglitazone reduced post prandial hypertriglyceridaemia through an effect on both absorbed and hepatically synthesised triglycerides.

adjustment for baseline covariates points to consider on the use of statistical methods for flexible design and analysis of confirmatory clinical trials points to consider on clinical pharmacokinetic investigation of the pharmacokinetics of peptides and proteins note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal function points to consider on the evaluation of the pharmacokinetics of medicinal products in the paediatric population note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with hepatic impairment note for guidance on clinical investigation of medicinal products for the treatment of psoriasis points to consider on allergic rhino-conjuctivitis addendum to the note for guidance on modified release oral and transdermal dosage forms:
note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with impaired renal functionpoints to consider on the evaluation of the pharmacokinetics of medicinal products in the paediatric population note for guidance on the evaluation of the pharmacokinetics of medicinal products in patients with hepatic impairment note for guidance on clinical investigation of medicinal products for the treatment of psoriasis points to consider on allergic rhino-conjuctivitis addendum to the note for guidance on modified release oral and transdermal dosage forms: